News

Video

Trastuzumab Deruxtecan in Patients With HER2+ Advanced/Metastatic Breast Cancer With or Without Brain Metastases: DESTINY-Breast12 Primary Results

Dr. Sara A. Hurvitz presents the primary results from the DESTINY-Breast12 trial, highlighting the efficacy and safety of trastuzumab deruxtecan in patients with HER2-positive advanced/metastatic breast cancer, including those with stable or active brain metastases​.

Video Player is loading.
Current Time 0:00
Duration 13:05
Loaded: 1.25%
Stream Type LIVE
Remaining Time 13:05
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
Safety and Efficacy of BAY 2927088 in Patients with HER2-Mutant NSCLC: Expansion Cohort from the Phase I/II SOHO-01 Study
Safety and Efficacy of BAY 2927088 in Patients with HER2-Mutant NSCLC: Expansion Cohort from the Phase I/II SOHO-01 Study
Tagraxofusp Achieves Anti-tumor Activity With Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
First results of nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability high/ mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW
First results of nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability high/ mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW
CDAC CLL
Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase 1 CaDAnCe-101 study
Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
Phase 3 AMPLIFY Trial
Fixed-Duration Acalabrutinib plus Venetoclax With or Without Obinutuzumab versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial
RLY-2608
Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor, in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial
BOVen
Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow Up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)
RMC-6236
Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)
Related Content